Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361281 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL29362992 | 0.88 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL24522311 | 0.88 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL31429037 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL1428940 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL1428531 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL28460399 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL8400871 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL29360693 | 0.81 | KDM4E (0.51) | KDM4EMAPTMEN1KMT2ACCNB2 | |
| SCHEMBL24522321 | 0.81 | KDM4E (0.51) | KDM4EMAPTMEN1KMT2ACCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114206857-B | Benzofuranyl N-acylhydrazone derivatives and pharmaceutical compositions comprising the same | 韩国生命工学研究院 | 2024-09-06 | — | — | CN | disclosed |
| US-20230293487-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4186503-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | Korea Research Institute of Bioscience and Biotechnology (KR) | 2023-05-31 | — | — | EP | disclosed |
| CN-116157120-A | Anti-inflammatory compositions comprising benzofuranyl N-acylhydrazone derivatives | 韩国生命工学研究院 | 2023-05-23 | — | — | CN | disclosed |
| EP-4015516-A1 | BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2022-06-22 | — | — | EP | disclosed |
| CN-114206857-A | Benzofuranyl N-acylhydrazone derivatives and pharmaceutical compositions containing the same | 韩国生命工学研究院 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022019663-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | 한국생명공학연구원 | 2022-01-27 | — | — | WO | disclosed |
| EP-3538529-B1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-KB PATHWAYS | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT (DE) | 2022-01-19 | — | — | EP | disclosed |
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2021-06-08 | — | — | US | disclosed |
| WO-2021010731-A1 | BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 한국생명공학연구원 | 2021-01-21 | — | — | WO | disclosed |
| EP-3538529-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2019-09-18 | — | — | EP | disclosed |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | US | disclosed |
| CN-109963850-A | The selective depressant of genotoxicity stress-induced IKK/NF- kB pathway | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 2019-07-02 | — | — | CN | disclosed |
| WO-2018087389-A1 | SELECTIVE INHIBITORS OF GENOTOXIC STRESS-INDUCED IKK/NF-kB PATHWAYS | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028084-B2 | Selective inhibitors of gentotoxic steress-induced IKK/NF-κB pathways | IKBKB, NFKBIA, IKBKE | ALDH1A1 3837/4885KDM4E 2954/4885MAPT 2979/4885 |
| US-20190276452-A1 | SELECTIVE INHIBITORS OF GENTOTOXIC STERESS-INDUCED IKK/NF-KB PATHWAYS | IKBKB, NFKBIA, IKBKE | ALDH1A1 3972/4885KDM4E 2948/4885MAPT 2845/4885 |
| US-20230293487-A1 | ANTI-INFLAMMATORY COMPOSITION COMPRISING BENZOFURAN-BASED N-ACYLHYDRAZONE DERIVATIVES | RELA, NFKBIA, IKBKG | ALDH1A1 1094/4885KDM4E 2006/4885MAPT 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.